Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

CONCLUSIONS: FAP-IL2v had a manageable safety profile and showed initial signs of antitumor activity in advanced/metastatic solid tumors.PMID:38630781 | DOI:10.1158/1078-0432.CCR-23-3567

Source: Clinical Cancer Research - April 17, 2024 Category: Cancer & Oncology Authors: Neeltje Steeghs Carlos Gomez-Roca Kristoffer S Rohrberg Morten Mau-S ørensen Debbie Robbrecht Josep Tabernero Samreen Ahmed Maria E Rodriguez-Ruiz Caroline Ardeshir Daniela Schmid Nassim Sleiman Carl Watson Hanna Piper-Lepoutre David Dejardin Stefan Ever Source Type: research